Affiliations: Department of Molecular, Cellular and Developmental
Biology, Yale University, New Haven, CT, USA | Department of Genetics, Stanford University School of
Medicine, Stanford, CA, USA
Note: [] Corresponding author: Michael Snyder, 300 Pasteur Drive, Alway
M-344, Department of Genetics, Stanford University School of Medicine,
Stanford, CA 94305, USA. Tel.: +1 650 736 8099; Fax: +1 650 725 1534; E-mail:
mpsnyder@stanford.edu
Abstract: Our understanding of human disease and potential therapeutics is
improving rapidly. In order to take advantage of these developments it is
important to be able to identify disease markers. Many new high-throughput
genomics and proteomics technologies are being implemented to identify
candidate disease markers. These technologies include protein microarrays,
next-generation DNA sequencing and mass spectrometry platforms. Such methods
are particularly important for elucidating the repertoire of molecular markers
in the genome, transcriptome, proteome and metabolome of patients with diseases
such as cancer, autoimmune diseases, and viral infections, resulting from the
disruption of many biological pathways. These new technologies have identified
many potential disease markers. These markers are expected to be valuable to
achieve the promise of truly personalized medicine.
Keywords: Systems biology, disease markers, cancer, autoimmune disease, protein microarray, mass spectrometry, Next-generation sequencing
